Sugi Predict

Sugi Predict / Compounds / SCHEMBL29397495

SCHEMBL29397495

SCHEMBL29397495

CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SIRT6 Q8N6T7 1/20 0.63
▸ SIRT1 Q96EB6 1/20 0.63
▸ ITGB3 P05106 3/20 0.54
▸ ITGA2B P08514 3/20 0.54
▸ CA1 P00915 2/20 0.52
▸ CA2 P00918 2/20 0.52
▸ TLR2 O60603 2/20 0.51
▸ FOLH1 Q04609 1/20 0.45
▸ SIRT5 Q9NXA8 1/20 0.44
▸ GNPAT O15228 1/20 0.43
▸ CPA1 P15085 1/20 0.42
▸ CPA2 P48052 1/20 0.42
▸ CPA4 Q9UI42 1/20 0.42
▸ NMT2 O60551 1/20 0.42
▸ NMT1 P30419 1/20 0.42
▸ GLO1 Q04760 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29394505 0.97 SIRT6 (0.60) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL29871873 0.94 SIRT6 (0.58) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL20964866 0.88 SIRT6 (0.63) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL29396814 0.85 SIRT6 (0.58) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL29444177 0.85 SIRT6 (0.68) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL31099442 0.85 SIRT6 (0.47) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL29531200 0.85 SIRT6 (0.47) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL20208589 0.85 SIRT6 (0.64) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL13554867 0.85 SIRT6 (0.47) SIRT6SIRT1ITGB3ITGA2BCA1
SCHEMBL4188063 0.84 PTGS1 (0.46) SIRT6SIRT1ITGB3ITGA2BCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154270-A1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF PFIZER INC. (US) 2025-05-15 — — US claimed
EP-4482853-A1 ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES RESOTHER PHARMA A/S (DK) 2025-01-01 — — EP claimed
CN-118891273-A Annexin A1 derived polypeptide analogs 雷索特制药股份有限公司 2024-11-01 — — CN claimed
US-20230357417-A1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF PFIZER INC. (US) 2023-11-09 — — US claimed
US-20230303640-A1 EXENDIN-4 PEPTIDE ANALOGS TXP PHARMA AG (CH) 2023-09-28 — — US claimed
US-20230295255-A1 ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES RESOTHER PHARMA APS (DK) 2023-09-21 — — US claimed
WO-2023161323-A1 ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES RESOTHER PHARMA A/S (DK) 2023-08-31 — — WO claimed
CN-116390938-A Exendin-4 analogues TXP制药股份有限公司 2023-07-04 — — CN claimed
EP-4200320-A1 ANNEXIN A1-DERIVED POLYPEPTIDE ANALOGUES RESOTHER PHARMA A/S (DK) 2023-06-28 — — EP claimed
EP-4196495-A1 EXENDIN-4 PEPTIDE ANALOGUES TXP Pharma GmbH (CH) 2023-06-21 — — EP claimed
US-11613581-B2 Antibodies and antibody-drug conjugates specific for CD123 and uses thereof PFIZER, INC. (US) 2023-03-28 — — US claimed
US-11602525-B2 Antibody-drug conjugates with high drug loading RINAT NEUROSCIENCE CORP. (US) 2023-03-14 — — US claimed
US-20220133839-A1 PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) TXP PHARMA GMBH (CH) 2022-05-05 — — US claimed
WO-2022034062-A1 EXENDIN-4 PEPTIDE ANALOGUES TXP PHARMA AG (CH) 2022-02-17 — — WO claimed
US-20260139067-A1 CDCP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES BETH ISRAEL DEACONESS MEDICAL CENTER (US) 2026-05-21 — — US disclosed
EP-4716554-A1 PD-L1 AND TROP-2 TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF Allygen Group (KY) 2026-04-01 — — EP disclosed
US-12559534-B2 Modified IL-2 proteins, peg conjugates, and uses thereof CSPC Megalith Biopharmaceutical Co., Ltd. (CN) 2026-02-24 — — US disclosed
CN-114245802-A Modified IL-2 proteins, PEG conjugates and uses thereof 石药集团巨石生物制药有限公司 2022-03-25 — — CN disclosed
US-11279764-B2 Antibodies specific for epidermal growth factor receptor variant III and their uses PFIZER INC. (US) 2022-03-22 — — US disclosed
WO-2022034062-A1 EXENDIN-4 PEPTIDE ANALOGUES TXP PHARMA AG (CH) 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139067-A1 CDCP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES DOCK2, CD2BP2, CDV3 SIRT6 4426/4885SIRT1 4743/4885ITGB3 1066/4885
US-20230357417-A1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF CD2, CD22, ENTPD3 SIRT6 2423/4885SIRT1 3666/4885ITGB3 46/4885
US-20250154270-A1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF CD2, CD22, ENTPD3 SIRT6 2423/4885SIRT1 3666/4885ITGB3 46/4885
US-11602525-B2 Antibody-drug conjugates with high drug loading GATD3, GLUL, SLC7A11 SIRT6 998/4885SIRT1 2337/4885ITGB3 808/4885
US-12559534-B2 Modified IL-2 proteins, peg conjugates, and uses thereof IL2, IL2RA, ILF2 SIRT6 3639/4885SIRT1 3902/4885ITGB3 1388/4885
US-11279764-B2 Antibodies specific for epidermal growth factor receptor variant III and their uses EGFR, ERBB3, ERBB2 SIRT6 4245/4885SIRT1 4838/4885ITGB3 140/4885
US-11613581-B2 Antibodies and antibody-drug conjugates specific for CD123 and uses thereof CD2, CD22, ENTPD3 SIRT6 2423/4885SIRT1 3666/4885ITGB3 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.